Are There Differences in the Demographics and Clinical Outcomes Between Asian and European Patients Treated With the COMBO Dual Therapy Stent in the REDUCE Trial Populations?

Author:

Wan Ahmad Wan Azman1ORCID,Benit Edouard2ORCID,Camaro Cyril3ORCID,Kedhi Elvin4,Rasoul Saman5,Barbieri Lucia6ORCID,Lalmand Jacques7,J van der Schaaf René8,Hai Koh Tian9ORCID,W van‘t Hof Arnoud5,W Lee Stephen10ORCID,Roolvink Vincent11,A Brouwer Marc3,De Luca Giuseppe6,Suryapranata Harry3

Affiliation:

1. Department of Medicine, University Malaya Medical Centre, Kuala Lumpur, Malaysia

2. Department of Cardiology, Jessa Ziekenhuis, Hasselt, Belgium

3. Department of Cardiology, Radboud University Medical Centre, Nijmegen, the Netherlands

4. Department of Cardiology, AZ Sint-Jan, Brugge, Belgium

5. Department of Cardiology, Maastricht University Medical Center, Maastricht, the Netherlands

6. Department of Cardiology, AOU Maggiore della Carità, Eastern Piedmont University, Novara, Italy

7. Department of Cardiology, Centre Hospitalier Universitaire, Charleroi, Belgium

8. Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands

9. Department of Cardiology, National Heart Center, Singapore, Singapore

10. Department of Cardiology, Queen Mary Hospital, University of Hong Kong, Hong Kong, China

11. Department of Cardiology, Isala Hospital, Zwolle, the Netherlands

Abstract

Background: This study aimed to assess differences in clinical characteristics and outcomes between Asian and European patients treated with the COMBO dual therapy stent in the REDUCE trial. Methods: In the REDUCE trial, 1,496 patients who underwent successful COMBO stent implantation were randomised to 3- or 12-month dual antiplatelet therapy groups. Of these, 449 (30%) were Asian and 1,047 (70%) were European. Given that no significant differences were observed between the 3- and 12-month dual antiplatelet therapy cohorts for both sites, the overall data of Asian patients were compared with those of European patients in terms of clinical characteristics and outcomes. Results: The Asian cohort was younger and comprised fewer women than the European cohort. They also had more cases of type 2 diabetes (33.0% versus 15.1%), hypercholesterolaemia (54.6% versus 41.7%) and hypertension (55.7% versus 48.5%) but had fewer previous interventions compared with European patients. Regarding procedures, Asian patients had more cases of infarct-related vessel in the left anterior descending artery. The primary endpoint indices among Asian patients at 90, 180, 360 and 720 days were lower than those among European patients, which can be attributed to the lower number of cases of target-vessel revascularisation, bleeding (Bleeding Academic Research Consortium classification II, III or V) and MI among the Asian cohort. Conclusion: Despite having a higher incidence of cardiovascular risk factors, more ST-elevation MI cases and more cases of culprit lesion located at the proximal left anterior descending artery, Asian patients in the REDUCE trial showed lower trends of target-vessel revascularisation, bleeding and MI than European patients in the REDUCE trial.

Publisher

Radcliffe Media Media Ltd

Reference13 articles.

1. de Winter RJ, Chandrasekhar J, Kalkman DN, et al. 1-year clinical outcomes of all-comer patients treated with the dual-therapy COMBO stent: primary results of the COMBO collaboration. JACC Cardiovasc Interv 2018;11:1969–78. https://doi.org/10.1016/j.jcin.2018.04.038; PMID: 30286855.

2. Kalkman DN, Kerkmeijer LS, Woudstra P, et al. Three-year clinical outcomes after dual-therapy COMBO stent placement: insights from the REMEDEE registry. Catheter Cardiovasc Interv 2019;94:342–7. https://doi.org/10.1002/ccd.28047; PMID: 30565371.

3. Kalkman DN, Chandrasekhar J, de Winter RJ, Mehran R. Current evidence for the safety and efficacy of the bio-engineered dual therapy COMBO stent. Minerva Cardioangiol 2018;66:262–72. https://doi.org/10.23736/S0026-4725.18.04612-1; PMID: 29381028.

4. Saito S, Krucoff MW, Nakamura S, et al. Japan–United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich’s Combo StEnt (Japan–USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome. Eur Heart J 2018;39:2460–8. https://doi.org/10.1093/eurheartj/ehy275; PMID: 29931092.

5. De Luca G, Damen SA, Camaro C, et al. Final results of the randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial). EuroIntervention 2019;15:e990–8. https://doi.org/10.4244/EIJ-D-19-00539; PMID: 31422929.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3